Quantbot Technologies LP Has $3.88 Million Holdings in DaVita Inc. $DVA

Quantbot Technologies LP reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 46.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,165 shares of the company’s stock after selling 25,546 shares during the quarter. Quantbot Technologies LP’s holdings in DaVita were worth $3,875,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in DVA. Man Group plc raised its stake in shares of DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after acquiring an additional 269,081 shares during the last quarter. Norges Bank bought a new position in DaVita in the 2nd quarter valued at $32,986,000. Todd Asset Management LLC acquired a new position in DaVita in the third quarter worth $21,842,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of DaVita by 132.1% during the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after purchasing an additional 150,318 shares during the last quarter. Finally, Rakuten Investment Management Inc. acquired a new stake in shares of DaVita in the third quarter valued at $19,875,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of NYSE:DVA opened at $156.28 on Monday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $157.91. The business’s 50-day moving average is $124.18 and its 200-day moving average is $125.91. The company has a market capitalization of $10.44 billion, a price-to-earnings ratio of 15.77, a P/E/G ratio of 0.55 and a beta of 0.93.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. The company had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DVA. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Barclays increased their target price on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, TD Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $155.80.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.